Clinical and Research Applications of Carotid Intima-Media Thickness

American Journal of Cardiology

Volumn 103, Issue 9, 2009, Pages 1316-1320

  Sharma, Kavita ^a   Blaha, Michael J ^a   Blumenthal, Roger S ^a   Musunuru, Kiran ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID INTIMA MEDIA THICKNESS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HEART DEATH; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; INTIMA; INTRAVASCULAR ULTRASOUND; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANIMALS; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID STENOSIS; CORONARY DISEASE; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 65249088072     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.020     Document Type: Editorial

References (30)

1. Kastelein J.J.P., Akdim F., Stroes E.S.G., Zwinderman A.H., Bots M.L., Stalenhoef A.F.H., Visseren F.L.J., Sijbrands E.J.G., Trip M.D., Stein E.A., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia (ENHANCE). N Engl J Med 358 (2008) 1431-1443
2. Stein J.H., Korcarz C.E., Hurst R.T., Lonn E., Kendall C.B., Mohler E.R., Najjar S.S., Rembold C.M., and Post W.S. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiography 21 (2008) 93-111
3. Chambless L.E., Folsom A.R., Clegg L.X., Sharrett A.R., Shahar E., Nieto F.J., Rosamond W.D., and Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 151 (2000) 478-487
4. Chambless L.E., Heiss G., Folsom A.R., Rosamond W., Szklo M., Sharrett A.R., and Clegg L.X. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 146 (1997) 483-494
5. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
6. Davis P.H., Dawson J.D., Mahoney L.T., and Lauer R.M. Increased carotid intimal-media thickness and coronary calcification are related in young and middle-aged adults: the Muscatine study. Circulation 100 (1999) 838-842
7. Davis P.H., Dawson J.D., Riley W.A., and Lauer R.M. Carotid intima-media thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation 104 (2001) 2815-2819
8. Urbina E.M., Srinivasan S.R., Tang R., Bond M.G., Kieltyka L., and Berenson G.S. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (the Bogulasa Heart Study). Am J Cardiol 90 (2002) 953-958
9. Tzou W.S., Douglas P.S., Srinivasan S.R., Bond M.G., Tang R., Chen W., Berenson G.S., and Stein J.H. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogulasa Heart Study. J Am Coll Cardiol 46 (2005) 457-463
10. Chen W., Srinivasan S.R., Xu J., and Berenson G.S. Effect of parental coronary artery disease on adverse effects of the metabolic syndrome and aging on carotid artery intima-media thickness (from the Bogulasa Heart Study). Am J Cardiol 102 (2008) 180-183
11. Ye Z., Cheng H., Chiou K., and Charng M. Relation of C-reactive protein and carotid intima-media thickness in Taiwanese with familial hypercholesterolemia. Am J Cardiol 102 (2008) 184-187
12. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., Hinds D.A., Pennacchio L.A., Tybjaerg-Hansen A., Folsom A.R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007) 1488-1491
13. Assimes T.L., Knowles J.W., Basu A., Iribarren C., Southwick A., Tang H., Absher D., Li J., Fair J.M., Rubin G.D., Sidney S., et al. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet 7 (2008) 2320-2328
14. Samani N.J., Raitakari O.T., Sipilä K., Tobin M.D., Schunkert H., Juonala M., Braund P.S., Erdmann J., Viikari J., Moilanen L., et al. Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis. Arterioscler Thromb Vasc Biol 28 (2008) 1679-1683
15. Cunnington MS, Mayosi BM, Hall DH, Avery PJ, Farrall M, Vickers MA, Watkins H, Keavney B. Novel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid artery intima-media thickness or intermediate risk phenotypes. Atherosclerosis. In press.
16. Folsom A.R., Kronmal R.A., Detrano R.C., O'Leary D.H., Bild D.E., Bluemke D.A., Budoff M.J., Liu K., Shea S., Szklo M., et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 168 (2008) 1333-1339
17. Desai M.Y., and Bluemke D.A. Atherosclerosis imaging using MR imaging: current and emerging applications. Magn Reson Imaging Clin N Am 13 (2005) 171-180
18. Fayad Z.A., Fuster V., Nikolaou K., and Becker C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation 106 (2002) 2026-2034
19. Corti R., Fuster V., Fayad Z.A., Worthley S.G., Helft G., Chaplin W.F., Muntwyler J., Viles-Gonzalez J.F., Weinberger J., Smith D.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 46 (2005) 106-112
20. Lima J.A., Desai M.Y., Steen H., Warren W.P., Gautam S., and Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 (2004) 2336-2341
21. Yonemura A., Momiyama Y., Fayad Z.A., Ayaori M., Ohmori R., Higashi K., Kihara T., Sawada S., Iwamoto N., Ogura M., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733-742
22. Thompson J.B., Blaha M., Resar J.R., Blumenthal R.S., and Desai M.Y. Strategies to reverse atherosclerosis: an imaging perspective. Curr Treat Options Cardiovasc Med 10 (2008) 283-293
23. Espeland M.A., O'Leary D.H., Terry J.G., Morgan T., Evans G., and Mudra H. Carotid intima-media thickness as a surrogate marker for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 6 (2005) 3
24. Boissel J.-P., Collet J.-P., Moleur P., and Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharm 43 (1992) 235-244
25. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Statist Med 8 (1989) 431-440
26. Hodis H.N., Mack W.J., LaBree L., Selzer R.H., Liu C.-R., Liu C.-H., and Azen S.P. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128 (1998) 262-269
27. Crouse III J.R., Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O'Leary D.H., Grobbee D.E., and Bots M.L. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis (METEOR trial). JAMA 297 (2007) 1344-1353
28. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
29. Kapur N.K., and Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 4 (2008) 341-345
30. Cannon C.P., Giugliano R.P., Blazing M.A., Harrington R.A., Peterson J.L., Sisk C.M., Strony J., Musliner T.A., McCabe C.H., Veltri E., et al., IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 156 (2008) 826-832